RecruitingNCT06026592

Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

30 participants

Start Date

Sep 2, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a potential diagnostic tool to monitor the rejection status of the kidney transplant. It has been suggested that dd-cfDNA is increasing in the blood of kidney transplant patient presenting a graft rejection. In this project, investigators proposed a different approach to predict and characterize kidney transplant rejection/dysfunction based on the quantification of epigenetic signatures present on the donor-cell-free DNA. In 2018, Moss et al. develops a deconvolution model capable of identifying the tissue origin of circulating DNA by taking advantage of its epigenetic properties. The study confirmed that the cell-free DNA circulating in healthy subjects comes mainly from blood cells and endothelial cells, but not from kidney cells. In this study, researchers investigate the evolution of blood renal-specific cell-free DNA amount in patient with chronic kidney disease before and after the transplantation surgery by testing a set of renal-specific epigenetic markers. The purpose of this study is to identify the biological noise of "native kidney" on renal-specific cell-free DNA and to compare it with signal coming from "transplanted kidney".


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age ≥ 18 years old
  • With end-stage renal failure
  • Summoned for a kidney transplant at Pitié Salpêtrière Hospital
  • Having been informed of the study and not objecting to the study having given free and informed written consent for the genetic analysis
  • Benefiting from a social security scheme (excluding AME)

Exclusion Criteria1

  • Under legal protective measures (curatorship or guardianship, under judicial safeguard).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICdetermination of circulating biomarkers of renal origin circulating biomarkers of renal origin

The extracted circulating DNA will be extracted and converted using the methylation kit. Finally, circulating DNA will be analyzed using the PCR mix developed by CGenetix, quantifying tubular and glomerular biomarkers (patented technology).


Locations(1)

Pitié-Salpétriêre Hospital

Paris, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06026592


Related Trials